Pharmaceutical Compositions
AssigneeVertex Pharmaceuticals Incorporated
InventorsKevin John Bittorf, Jeffrey P. Kastra, Filipe Gaspar
Life of this patent
Estimating the term…
Abstract
Forms and formulations of VX-950 and uses thereof.
Claims19
1-33. (canceled)
A solid dispersion comprising 55% VX-950, about 19.6% of an HPMC polymer, about 24.4% of an HPMCAS polymer, and about 1% of a surfactant.
A solid dispersion comprising about 55% VX-950, about 29.3% of an HPMC polymer, about 14.7% of an HPMCAS polymer, and about 1% of a surfactant.
A solid dispersion comprising about 60% VX-950, about 14.6% of an HPMC polymer, about 24.4% of an HPMCAS polymer, and about 1% of a surfactant.
A solid dispersion comprising about 65% VX-950, about 17% of an HPMC polymer, about 17% of an HPMCAS polymer, and about 1% of a surfactant.
A solid dispersion comprising about 70% VX-950, about 19.3% of an HPMC polymer, about 9.7% of an HPMCAS polymer, and about 1% of a surfactant.
39-57. (canceled)
A pharmaceutical composition comprising:
- an amorphous solid dispersion of VX-950 comprising about 55% to about 70% wt/wt of the pharmaceutical composition,
- a surfactant, wherein the surfactant is sodium lauryl sulfate or Vitamin E TPGS and comprises about 1% wt/wt of the pharmaceutical composition, and
- a plurality of polymers comprises HPMC and HPMCAS, and comprises about 44% to about 29% wt/wt of the pharmaceutical composition, thereby totaling 100% wt/wt of the composition.
A pharmaceutical composition comprising:
- an amorphous solid dispersion of VX-950 comprising about 55% wt/wt of the pharmaceutical composition,
- a plurality of polymers comprising about 44% wt/wt of the pharmaceutical composition
- a surfactant, wherein the surfactant is sodium lauryl sulfate or Vitamin E TPGS and comprises about 1% wt/wt of the pharmaceutical composition.
(canceled)
A pharmaceutical composition comprising:
- an amorphous solid dispersion of VX-950 comprising about 60% wt/wt of the pharmaceutical composition,
- a plurality of polymers comprising about 39% wt/wt of the pharmaceutical composition
- a surfactant, wherein the surfactant is sodium lauryl sulfate or Vitamin E TPGS and comprises about 1% wt/wt of the pharmaceutical composition.
A pharmaceutical composition comprising:
- an amorphous solid dispersion of VX-950 comprising about 65% wt/wt of the pharmaceutical composition,
- a plurality of polymers comprising about 34% wt/wt of the pharmaceutical composition
- a surfactant, wherein the surfactant is sodium lauryl sulfate or Vitamin E TPGS and comprises about 1% wt/wt of the pharmaceutical composition.
A pharmaceutical composition comprising:
- an amorphous solid dispersion of VX-950 comprising about 70% wt/wt of the pharmaceutical composition,
- a plurality of polymers comprising about 29% wt/wt of the pharmaceutical composition
- a surfactant, wherein the surfactant is sodium lauryl sulfate or Vitamin E TPGS and comprises about 1% wt/wt of the pharmaceutical composition.
69-85. (canceled)
Dependencies are inferred from the claim text.